MXPA02005236A - Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos. - Google Patents

Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos.

Info

Publication number
MXPA02005236A
MXPA02005236A MXPA02005236A MXPA02005236A MXPA02005236A MX PA02005236 A MXPA02005236 A MX PA02005236A MX PA02005236 A MXPA02005236 A MX PA02005236A MX PA02005236 A MXPA02005236 A MX PA02005236A MX PA02005236 A MXPA02005236 A MX PA02005236A
Authority
MX
Mexico
Prior art keywords
methods
compositions
treating lupus
antibody affinity
treatment
Prior art date
Application number
MXPA02005236A
Other languages
English (en)
Inventor
D Linnik Matthew
Original Assignee
Jolla Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jolla Pharma filed Critical Jolla Pharma
Publication of MXPA02005236A publication Critical patent/MXPA02005236A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion proporciona metodos para identificar individuos apropiados para el tratamiento del lupus, y metodos para observar el tratamiento, con base en la medicion de afinidades de anticuerpos, asi como el tratamiento del lupus con base en la medicion de afinidades de anticuerpos. El tratamiento ocasiona la administracion de un conjugado que comprende una molecula de valencia de plataforma no inmunogenica y al menos dos epitopes de ADN de hebra doble, tal como moleculas de ADN, que se enlazan a los anticuerpos anti-ADN del paciente.
MXPA02005236A 1999-11-28 2000-11-28 Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos. MXPA02005236A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16771699P 1999-11-28 1999-11-28
PCT/US2000/042307 WO2001041813A2 (en) 1999-11-28 2000-11-28 Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof

Publications (1)

Publication Number Publication Date
MXPA02005236A true MXPA02005236A (es) 2004-03-19

Family

ID=22608518

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02005236A MXPA02005236A (es) 1999-11-28 2000-11-28 Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos.

Country Status (11)

Country Link
US (2) US7081242B1 (es)
EP (1) EP1233791A2 (es)
JP (1) JP2003516526A (es)
KR (1) KR20020059808A (es)
CN (2) CN1399562A (es)
AU (1) AU783282C (es)
CA (1) CA2391944A1 (es)
HK (1) HK1045944A1 (es)
MX (1) MXPA02005236A (es)
NO (1) NO20022441L (es)
WO (1) WO2001041813A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
EP1233791A2 (en) 1999-11-28 2002-08-28 La Jolla Pharmaceutical Company Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof
US20030114405A1 (en) * 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
WO2004060320A2 (en) * 2002-12-27 2004-07-22 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
WO2004089422A2 (en) * 2003-03-30 2004-10-21 La Jolla Pharmaceutical Co. Methods of treating and monitoring systemic lupus erythematosus in individuals
US20060229270A1 (en) * 2005-03-10 2006-10-12 La Jolla Pharmaceutical Company Methods of treating proteinuria by reducing double-stranded DNA antibodies
US8492347B2 (en) * 2007-10-17 2013-07-23 The Regents Of The University Of California Peptide for induction of immune tolerance as treatment for systemic lupus erythematosus
CN102477079A (zh) * 2010-11-24 2012-05-30 中国人民解放军军事医学科学院基础医学研究所 一种新型多肽在系统性红斑狼疮诊断中的应用
WO2012116210A2 (en) * 2011-02-23 2012-08-30 The Regents Of The University Of California Peptide for the induction of immune tolerance as treatment for systemic lupus erythematosus

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022544A (en) 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5370871A (en) 1983-01-24 1994-12-06 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5126131A (en) 1983-01-24 1992-06-30 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
US5162515A (en) 1990-01-16 1992-11-10 La Jolla Pharmaceutical Company Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5391785A (en) 1990-01-16 1995-02-21 La Jolla Pharmaceutial Company Intermediates for providing functional groups on the 5' end of oligonucleotides
WO1992005801A1 (en) 1990-10-04 1992-04-16 University Of Virginia Alumni Patents Foundation Primate erythrocyte bound monoclonal antibody heteropolymers
IE922292A1 (en) 1991-07-15 1993-01-27 Jolla Pharma Modified phosphorous intermediates for providing functional¹groups on the 5' end of oligonucleotides
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
ATE359830T1 (de) 1993-09-08 2007-05-15 Jolla Pharma Chemisch definierten nicht-polymer wertigen plattformmolokülen und ihren konjugaten
ES2207646T3 (es) 1994-02-28 2004-06-01 The University Of Virginia Patent Foundation Heteropolimeros basados en antigenos para el tratamiento de enfermedades autoinmunitarias.
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US5856464A (en) 1995-06-07 1999-01-05 Lajolla Pharmaceutical Company Selective capping solution phase oligonucleotide synthesis
US5817752A (en) 1996-06-06 1998-10-06 La Jolla Pharmaceutical Company Cyclic polypeptides comprising a thioether linkage and methods for their preparation
WO1997046251A1 (en) 1996-06-06 1997-12-11 Lajolla Pharmaceutical Company aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES
DK0974550T3 (da) 1997-04-11 2004-12-06 Chiyoda Chem Eng Construct Co Katalysator til fremstilling af syntsegas og fremgangsmåde til fremstilling af carbonmonoxid
AU2583899A (en) 1998-02-04 1999-08-23 Invitrogen Corporation Microarrays and uses therefor
JP4078032B2 (ja) 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル，コーポレイション 近位の反応性基を持つポリ（エチレングリコール）誘導体
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
AU765585B2 (en) 1998-09-10 2003-09-25 University Of Virginia Patent Foundation Antibodies to C3b(I) for delivery of diagnostic and therapeutic agents to cancer cells
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
WO2000033887A2 (en) 1998-12-08 2000-06-15 La Jolla Pharmaceutical Company Methods and formulations for reducing circulating antibodies
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US20010010818A1 (en) 1998-12-09 2001-08-02 Engle Steven B. Methods and formulations for reducing circulating antibodies
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
KR20020022691A (ko) 1999-06-08 2002-03-27 와이즈먼 앤드루 아미노옥시기를 포함하는 원자가 플랫폼 분자
EP1233791A2 (en) 1999-11-28 2002-08-28 La Jolla Pharmaceutical Company Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof
AU2593901A (en) 1999-12-23 2001-07-03 Elusys Therapeutics, Inc. Therapeutic use of particles displaying pathogen-specific binding moieties
EP1284752A4 (en) 2000-04-26 2004-08-18 Elusys Therapeutics Inc BISPECIFIC MOLECULES AND USES THEREOF
EP1292337A2 (en) 2000-06-08 2003-03-19 La Jolla Pharmaceutical Multivalent platform molecules comprising high molecular weight polyethylene oxide
WO2002046208A2 (en) 2000-11-01 2002-06-13 Elusys Therapeutics, Inc. Method of producing biospecific molecules by protein trans-splicing
US20030077273A1 (en) 2001-05-17 2003-04-24 Linnik Matthew D. Methods of treating antibody-mediated pathologies using agents which inhibit CD21
US20030114405A1 (en) 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
WO2004060320A2 (en) 2002-12-27 2004-07-22 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
WO2004089422A2 (en) 2003-03-30 2004-10-21 La Jolla Pharmaceutical Co. Methods of treating and monitoring systemic lupus erythematosus in individuals

Also Published As

Publication number Publication date
US20060142229A1 (en) 2006-06-29
CA2391944A1 (en) 2001-06-14
AU783282C (en) 2006-04-06
WO2001041813A3 (en) 2002-01-03
NO20022441L (no) 2002-07-09
AU783282B2 (en) 2005-10-06
KR20020059808A (ko) 2002-07-13
CN1399562A (zh) 2003-02-26
AU3970201A (en) 2001-06-18
WO2001041813A2 (en) 2001-06-14
NO20022441D0 (no) 2002-05-23
JP2003516526A (ja) 2003-05-13
EP1233791A2 (en) 2002-08-28
CN101422614A (zh) 2009-05-06
HK1045944A1 (zh) 2002-12-20
US7081242B1 (en) 2006-07-25

Similar Documents

Publication Publication Date Title
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
EP2289550A3 (en) Ultra high affinity neutralizing antibodies
HUP0401591A2 (hu) Új receptor-nukleinsavak és- polipeptidek
DE60028970D1 (de) An her2 bindende peptidverbindungen
WO2002046222A3 (en) Compositions and methods for diagnosing alzheimer's disease
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
ATE196314T1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
DE69520149D1 (de) Tie-2 ligande, verfahren zu ihrer herstellung, und ihre anwendungen
WO2001018550A3 (en) Determination of adrenomedullin-binding proteins
EP1218368A4 (en) Compositions and Methods for Modulating Apoptosis in Cells Expressing BC1-2 Family Proteins
MXPA02005236A (es) Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos.
ATE235551T1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
WO2004094476A3 (en) Compositions and methods relating to stop-1
WO2004066933A3 (en) Compositions and methods for treating cancer using igsf9 and liv-1
BR0317161A (pt) Moléculas de ligação nogo a e uso farmacêutico das mesmas
NZ524329A (en) IgE receptor antagonists that compete with IgE134 for binding to the receptor
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
DE69621915D1 (de) Anti-dns-antikörpernachweis mittels erkennung und bindung telomerischer dns-sequenzen
ATE407944T1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
WO2002070563A3 (en) Nuclear hormone receptor ligand binding domain
PT1196188E (pt) Anticorpos monoclonais selectivos para o fcv e sua utilizacao para o tratamento de doencas associadas ao fcv
WO1996021675A3 (en) Capturing of microorganisms using complement components
WO2002036733A3 (en) Cd36 as a heat shock protein receptor and uses thereof
WO2004113566A3 (en) Disease related protein network
ATE364180T1 (de) Screeningverfahren mit bnpi und dnpi

Legal Events

Date Code Title Description
FG Grant or registration